Cynthia Ann Rask Net Worth

What's Cynthia Rask's mailing address?

Cynthia's mailing address filed with the SEC is C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON, PA, 19333.

Insiders trading at Zynerba Pharmaceuticals Inc

Over the last 9 years, insiders at Zynerba Pharmaceuticals Inc have traded over $154,101 worth of Zynerba Pharmaceuticals Inc stock and bought 224,703 units worth $2,383,877 . The most active insiders traders include John P. Butler, William J Federici a Michael Rapp. On average, Zynerba Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $12,515. The most recent stock trade was executed by Terri B Sebree on 12 September 2023, trading 12,401 units of ZYNE stock currently worth $16,493.

What does Zynerba Pharmaceuticals Inc do?

at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.

Zynerba Pharmaceuticals Inc executives and stock owners

Zynerba Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Armando Anido,
  Chairman of the Board, Chief Executive Officer
• Terri Sebree,
  President
• Armando Anido MBA,
  Chairman & CEO
• James Fickenscher,
  Chief Financial Officer, Vice President - Corporate Development
• Terri B. Sebree,
  Pres
• James E. Fickenscher,
  CFO, VP of Corp. Devel. & Treasurer
• Suzanne Hanlon,
  Vice President, General Counsel, Secretary
• William Roberts,
  Vice President, Investor Relations and Corporate Communications
• Pamela Stephenson,
  Independent Director
• Kenneth Moch,
  Independent Director
• Daniel Kisner,
  Independent Director
• William Federici,
  Independent Director
• John Butler,
  Independent Director
• Warren Cooper,
  Lead Independent Director
• Brian Rosenberger,
  Vice President - Commercial and Business Development
• Joseph Apostolico,
  VP of HR
• Suzanne M. Hanlon,
  Sec., VP & Gen. Counsel
• Dr. Joseph Palumbo,
  Chief Medical Officer
• Thomas L Harrison,
  Director
• Michael Rapp,
  10% owner
• Cynthia Ann Rask,
  Director
• Albert P Parker,
  Chief Legal Officer
• Richard A Baron,
  Chief Financial Officer
• Kenneth T Jones,
  See Remarks